Deltex Medical Group plc
Deltex Medical Group plc (DTXMF) Stock Competitors & Peer Comparison
See (DTXMF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DTXMF | $0.10 | +0.00% | 180.6M | -9.52 | -$0.01 | N/A |
| SMMNY | $28.18 | +0.51% | 126.5B | 25.86 | $1.09 | +1.05% |
| SEMHF | $54.72 | -3.83% | 61.4B | 25.33 | $2.16 | +1.81% |
| RYLPF | $25.69 | -1.24% | 24.4B | 85.63 | $0.30 | +3.70% |
| SONVY | $58.80 | -0.08% | 17.5B | 25.79 | $2.28 | +1.07% |
| SONVF | $288.61 | -3.73% | 17.2B | 25.34 | $11.39 | +1.81% |
| CHEOY | $102.47 | -0.67% | 13.4B | 55.69 | $1.84 | +1.36% |
| SNNUF | $14.94 | +1.29% | 13.1B | 31.79 | $0.47 | +2.51% |
| CHEOF | $195.55 | +1.30% | 12.8B | 52.71 | $3.71 | +1.42% |
| WILLF | $43.77 | -0.01% | 9B | 21.14 | $2.07 | N/A |
Stock Comparison
DTXMF vs SMMNY Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, SMMNY has a market cap of 126.5B. Regarding current trading prices, DTXMF is priced at $0.10, while SMMNY trades at $28.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas SMMNY's P/E ratio is 25.86. In terms of profitability, DTXMF's ROE is -0.41%, compared to SMMNY's ROE of +0.11%. Regarding short-term risk, DTXMF is more volatile compared to SMMNY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check SMMNY's competition here
DTXMF vs SEMHF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, SEMHF has a market cap of 61.4B. Regarding current trading prices, DTXMF is priced at $0.10, while SEMHF trades at $54.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas SEMHF's P/E ratio is 25.33. In terms of profitability, DTXMF's ROE is -0.41%, compared to SEMHF's ROE of +0.11%. Regarding short-term risk, DTXMF is more volatile compared to SEMHF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check SEMHF's competition here
DTXMF vs RYLPF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, RYLPF has a market cap of 24.4B. Regarding current trading prices, DTXMF is priced at $0.10, while RYLPF trades at $25.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas RYLPF's P/E ratio is 85.63. In terms of profitability, DTXMF's ROE is -0.41%, compared to RYLPF's ROE of +0.03%. Regarding short-term risk, DTXMF is more volatile compared to RYLPF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check RYLPF's competition here
DTXMF vs SONVY Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, SONVY has a market cap of 17.5B. Regarding current trading prices, DTXMF is priced at $0.10, while SONVY trades at $58.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas SONVY's P/E ratio is 25.79. In terms of profitability, DTXMF's ROE is -0.41%, compared to SONVY's ROE of +0.21%. Regarding short-term risk, DTXMF is more volatile compared to SONVY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check SONVY's competition here
DTXMF vs SONVF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, SONVF has a market cap of 17.2B. Regarding current trading prices, DTXMF is priced at $0.10, while SONVF trades at $288.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas SONVF's P/E ratio is 25.34. In terms of profitability, DTXMF's ROE is -0.41%, compared to SONVF's ROE of +0.22%. Regarding short-term risk, DTXMF is more volatile compared to SONVF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check SONVF's competition here
DTXMF vs CHEOY Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CHEOY has a market cap of 13.4B. Regarding current trading prices, DTXMF is priced at $0.10, while CHEOY trades at $102.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CHEOY's P/E ratio is 55.69. In terms of profitability, DTXMF's ROE is -0.41%, compared to CHEOY's ROE of +0.20%. Regarding short-term risk, DTXMF is more volatile compared to CHEOY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CHEOY's competition here
DTXMF vs SNNUF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, SNNUF has a market cap of 13.1B. Regarding current trading prices, DTXMF is priced at $0.10, while SNNUF trades at $14.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas SNNUF's P/E ratio is 31.79. In terms of profitability, DTXMF's ROE is -0.41%, compared to SNNUF's ROE of +0.08%. Regarding short-term risk, DTXMF is more volatile compared to SNNUF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check SNNUF's competition here
DTXMF vs CHEOF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CHEOF has a market cap of 12.8B. Regarding current trading prices, DTXMF is priced at $0.10, while CHEOF trades at $195.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CHEOF's P/E ratio is 52.71. In terms of profitability, DTXMF's ROE is -0.41%, compared to CHEOF's ROE of +0.20%. Regarding short-term risk, DTXMF is more volatile compared to CHEOF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CHEOF's competition here
DTXMF vs WILLF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, WILLF has a market cap of 9B. Regarding current trading prices, DTXMF is priced at $0.10, while WILLF trades at $43.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas WILLF's P/E ratio is 21.14. In terms of profitability, DTXMF's ROE is -0.41%, compared to WILLF's ROE of +0.25%. Regarding short-term risk, DTXMF is more volatile compared to WILLF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check WILLF's competition here
DTXMF vs WILYY Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, WILYY has a market cap of 8.6B. Regarding current trading prices, DTXMF is priced at $0.10, while WILYY trades at $20.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas WILYY's P/E ratio is 19.41. In terms of profitability, DTXMF's ROE is -0.41%, compared to WILYY's ROE of +0.25%. Regarding short-term risk, DTXMF is more volatile compared to WILYY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check WILYY's competition here
DTXMF vs GNGBY Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, GNGBY has a market cap of 5.8B. Regarding current trading prices, DTXMF is priced at $0.10, while GNGBY trades at $21.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas GNGBY's P/E ratio is 37.52. In terms of profitability, DTXMF's ROE is -0.41%, compared to GNGBY's ROE of +0.05%. Regarding short-term risk, DTXMF is more volatile compared to GNGBY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check GNGBY's competition here
DTXMF vs GNGBF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, GNGBF has a market cap of 5.7B. Regarding current trading prices, DTXMF is priced at $0.10, while GNGBF trades at $21.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas GNGBF's P/E ratio is 36.84. In terms of profitability, DTXMF's ROE is -0.41%, compared to GNGBF's ROE of +0.05%. Regarding short-term risk, DTXMF is more volatile compared to GNGBF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check GNGBF's competition here
DTXMF vs AMBBY Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, AMBBY has a market cap of 4.2B. Regarding current trading prices, DTXMF is priced at $0.10, while AMBBY trades at $15.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas AMBBY's P/E ratio is 70.05. In terms of profitability, DTXMF's ROE is -0.41%, compared to AMBBY's ROE of +0.06%. Regarding short-term risk, DTXMF is more volatile compared to AMBBY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check AMBBY's competition here
DTXMF vs NHNKY Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, NHNKY has a market cap of 4.1B. Regarding current trading prices, DTXMF is priced at $0.10, while NHNKY trades at $12.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas NHNKY's P/E ratio is 22.00. In terms of profitability, DTXMF's ROE is -0.41%, compared to NHNKY's ROE of +0.08%. Regarding short-term risk, DTXMF is more volatile compared to NHNKY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check NHNKY's competition here
DTXMF vs AMBFF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, AMBFF has a market cap of 4B. Regarding current trading prices, DTXMF is priced at $0.10, while AMBFF trades at $15.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas AMBFF's P/E ratio is 69.09. In terms of profitability, DTXMF's ROE is -0.41%, compared to AMBFF's ROE of +0.06%. Regarding short-term risk, DTXMF is more volatile compared to AMBFF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check AMBFF's competition here
DTXMF vs NHNKF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, NHNKF has a market cap of 2.5B. Regarding current trading prices, DTXMF is priced at $0.10, while NHNKF trades at $15.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas NHNKF's P/E ratio is 41.86. In terms of profitability, DTXMF's ROE is -0.41%, compared to NHNKF's ROE of +0.08%. Regarding short-term risk, DTXMF is more volatile compared to NHNKF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check NHNKF's competition here
DTXMF vs GNNDY Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, GNNDY has a market cap of 2.3B. Regarding current trading prices, DTXMF is priced at $0.10, while GNNDY trades at $48.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas GNNDY's P/E ratio is 18.76. In terms of profitability, DTXMF's ROE is -0.41%, compared to GNNDY's ROE of +0.08%. Regarding short-term risk, DTXMF is more volatile compared to GNNDY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check GNNDY's competition here
DTXMF vs GGNDF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, GGNDF has a market cap of 2.1B. Regarding current trading prices, DTXMF is priced at $0.10, while GGNDF trades at $14.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas GGNDF's P/E ratio is 16.53. In terms of profitability, DTXMF's ROE is -0.41%, compared to GGNDF's ROE of +0.08%. Regarding short-term risk, DTXMF is more volatile compared to GGNDF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check GGNDF's competition here
DTXMF vs MCRPF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, MCRPF has a market cap of 2.1B. Regarding current trading prices, DTXMF is priced at $0.10, while MCRPF trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas MCRPF's P/E ratio is -9.33. In terms of profitability, DTXMF's ROE is -0.41%, compared to MCRPF's ROE of -0.33%. Regarding short-term risk, DTXMF is more volatile compared to MCRPF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check MCRPF's competition here
DTXMF vs STSEY Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, STSEY has a market cap of 2B. Regarding current trading prices, DTXMF is priced at $0.10, while STSEY trades at $6.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas STSEY's P/E ratio is 39.41. In terms of profitability, DTXMF's ROE is -0.41%, compared to STSEY's ROE of +0.07%. Regarding short-term risk, DTXMF is more volatile compared to STSEY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check STSEY's competition here
DTXMF vs VTRLY Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, VTRLY has a market cap of 2B. Regarding current trading prices, DTXMF is priced at $0.10, while VTRLY trades at $14.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas VTRLY's P/E ratio is 42.80. In terms of profitability, DTXMF's ROE is -0.41%, compared to VTRLY's ROE of +0.04%. Regarding short-term risk, DTXMF is more volatile compared to VTRLY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check VTRLY's competition here
DTXMF vs OSSFF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, OSSFF has a market cap of 1.8B. Regarding current trading prices, DTXMF is priced at $0.10, while OSSFF trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas OSSFF's P/E ratio is 24.41. In terms of profitability, DTXMF's ROE is -0.41%, compared to OSSFF's ROE of +0.09%. Regarding short-term risk, DTXMF is more volatile compared to OSSFF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check OSSFF's competition here
DTXMF vs DWRKF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, DWRKF has a market cap of 1.8B. Regarding current trading prices, DTXMF is priced at $0.10, while DWRKF trades at $543.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas DWRKF's P/E ratio is 75.94. In terms of profitability, DTXMF's ROE is -0.41%, compared to DWRKF's ROE of N/A. Regarding short-term risk, DTXMF is more volatile compared to DWRKF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check DWRKF's competition here
DTXMF vs OSSUY Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, OSSUY has a market cap of 1.7B. Regarding current trading prices, DTXMF is priced at $0.10, while OSSUY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas OSSUY's P/E ratio is 23.53. In terms of profitability, DTXMF's ROE is -0.41%, compared to OSSUY's ROE of +0.09%. Regarding short-term risk, DTXMF is more volatile compared to OSSUY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check OSSUY's competition here
DTXMF vs MEDGF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, MEDGF has a market cap of 1.7B. Regarding current trading prices, DTXMF is priced at $0.10, while MEDGF trades at $83.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas MEDGF's P/E ratio is 33.30. In terms of profitability, DTXMF's ROE is -0.41%, compared to MEDGF's ROE of +0.16%. Regarding short-term risk, DTXMF is more volatile compared to MEDGF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check MEDGF's competition here
DTXMF vs DRWKF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, DRWKF has a market cap of 1.4B. Regarding current trading prices, DTXMF is priced at $0.10, while DRWKF trades at $67.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas DRWKF's P/E ratio is 9.40. In terms of profitability, DTXMF's ROE is -0.41%, compared to DRWKF's ROE of +0.09%. Regarding short-term risk, DTXMF is more volatile compared to DRWKF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check DRWKF's competition here
DTXMF vs DGWPF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, DGWPF has a market cap of 1.2B. Regarding current trading prices, DTXMF is priced at $0.10, while DGWPF trades at $57.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas DGWPF's P/E ratio is 7.94. In terms of profitability, DTXMF's ROE is -0.41%, compared to DGWPF's ROE of +0.09%. Regarding short-term risk, DTXMF is more volatile compared to DGWPF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check DGWPF's competition here
DTXMF vs ELEAF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, ELEAF has a market cap of 1.1B. Regarding current trading prices, DTXMF is priced at $0.10, while ELEAF trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas ELEAF's P/E ratio is 15.51. In terms of profitability, DTXMF's ROE is -0.41%, compared to ELEAF's ROE of +0.15%. Regarding short-term risk, DTXMF is more volatile compared to ELEAF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check ELEAF's competition here
DTXMF vs LFTSF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, LFTSF has a market cap of 1B. Regarding current trading prices, DTXMF is priced at $0.10, while LFTSF trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas LFTSF's P/E ratio is 23.35. In terms of profitability, DTXMF's ROE is -0.41%, compared to LFTSF's ROE of +0.07%. Regarding short-term risk, DTXMF is more volatile compared to LFTSF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check LFTSF's competition here
DTXMF vs MDRSF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, MDRSF has a market cap of 828.1M. Regarding current trading prices, DTXMF is priced at $0.10, while MDRSF trades at $66.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas MDRSF's P/E ratio is 196.12. In terms of profitability, DTXMF's ROE is -0.41%, compared to MDRSF's ROE of +0.01%. Regarding short-term risk, DTXMF is more volatile compared to MDRSF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check MDRSF's competition here
DTXMF vs XVIPF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, XVIPF has a market cap of 693M. Regarding current trading prices, DTXMF is priced at $0.10, while XVIPF trades at $22.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas XVIPF's P/E ratio is 59.46. In terms of profitability, DTXMF's ROE is -0.41%, compared to XVIPF's ROE of +0.07%. Regarding short-term risk, DTXMF is more volatile compared to XVIPF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check XVIPF's competition here
DTXMF vs CALZF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CALZF has a market cap of 584.3M. Regarding current trading prices, DTXMF is priced at $0.10, while CALZF trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CALZF's P/E ratio is 84.58. In terms of profitability, DTXMF's ROE is -0.41%, compared to CALZF's ROE of +0.07%. Regarding short-term risk, DTXMF is more volatile compared to CALZF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CALZF's competition here
DTXMF vs AVMR Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, AVMR has a market cap of 494.2M. Regarding current trading prices, DTXMF is priced at $0.10, while AVMR trades at $9.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas AVMR's P/E ratio is -18.34. In terms of profitability, DTXMF's ROE is -0.41%, compared to AVMR's ROE of -1.38%. Regarding short-term risk, DTXMF is more volatile compared to AVMR. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check AVMR's competition here
DTXMF vs CLVSF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CLVSF has a market cap of 459.8M. Regarding current trading prices, DTXMF is priced at $0.10, while CLVSF trades at $19.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CLVSF's P/E ratio is 31.61. In terms of profitability, DTXMF's ROE is -0.41%, compared to CLVSF's ROE of +0.19%. Regarding short-term risk, DTXMF is more volatile compared to CLVSF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CLVSF's competition here
DTXMF vs IOBCF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, IOBCF has a market cap of 407.5M. Regarding current trading prices, DTXMF is priced at $0.10, while IOBCF trades at $13.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas IOBCF's P/E ratio is 37.59. In terms of profitability, DTXMF's ROE is -0.41%, compared to IOBCF's ROE of +0.09%. Regarding short-term risk, DTXMF is more volatile compared to IOBCF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check IOBCF's competition here
DTXMF vs CSSPF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CSSPF has a market cap of 384M. Regarding current trading prices, DTXMF is priced at $0.10, while CSSPF trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CSSPF's P/E ratio is 92.00. In terms of profitability, DTXMF's ROE is -0.41%, compared to CSSPF's ROE of +0.16%. Regarding short-term risk, DTXMF is more volatile compared to CSSPF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CSSPF's competition here
DTXMF vs HYBT Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, HYBT has a market cap of 361.4M. Regarding current trading prices, DTXMF is priced at $0.10, while HYBT trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas HYBT's P/E ratio is N/A. In terms of profitability, DTXMF's ROE is -0.41%, compared to HYBT's ROE of -0.00%. Regarding short-term risk, DTXMF is more volatile compared to HYBT. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check HYBT's competition here
DTXMF vs EAPIF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, EAPIF has a market cap of 347.6M. Regarding current trading prices, DTXMF is priced at $0.10, while EAPIF trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas EAPIF's P/E ratio is -2.25. In terms of profitability, DTXMF's ROE is -0.41%, compared to EAPIF's ROE of -0.31%. Regarding short-term risk, DTXMF is more volatile compared to EAPIF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check EAPIF's competition here
DTXMF vs CYBQY Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CYBQY has a market cap of 266.8M. Regarding current trading prices, DTXMF is priced at $0.10, while CYBQY trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CYBQY's P/E ratio is -52.00. In terms of profitability, DTXMF's ROE is -0.41%, compared to CYBQY's ROE of -0.01%. Regarding short-term risk, DTXMF is more volatile compared to CYBQY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CYBQY's competition here
DTXMF vs BRSYF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, BRSYF has a market cap of 256.2M. Regarding current trading prices, DTXMF is priced at $0.10, while BRSYF trades at $6.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas BRSYF's P/E ratio is 61.64. In terms of profitability, DTXMF's ROE is -0.41%, compared to BRSYF's ROE of +0.07%. Regarding short-term risk, DTXMF is more volatile compared to BRSYF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check BRSYF's competition here
DTXMF vs CLLKF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CLLKF has a market cap of 245.2M. Regarding current trading prices, DTXMF is priced at $0.10, while CLLKF trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CLLKF's P/E ratio is -7.89. In terms of profitability, DTXMF's ROE is -0.41%, compared to CLLKF's ROE of -0.12%. Regarding short-term risk, DTXMF is more volatile compared to CLLKF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CLLKF's competition here
DTXMF vs HTLZF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, HTLZF has a market cap of 245.1M. Regarding current trading prices, DTXMF is priced at $0.10, while HTLZF trades at $1.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas HTLZF's P/E ratio is -159.01. In terms of profitability, DTXMF's ROE is -0.41%, compared to HTLZF's ROE of -0.03%. Regarding short-term risk, DTXMF is more volatile compared to HTLZF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check HTLZF's competition here
DTXMF vs BCCOY Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, BCCOY has a market cap of 221M. Regarding current trading prices, DTXMF is priced at $0.10, while BCCOY trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas BCCOY's P/E ratio is -7.27. In terms of profitability, DTXMF's ROE is -0.41%, compared to BCCOY's ROE of -0.12%. Regarding short-term risk, DTXMF is more volatile compared to BCCOY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check BCCOY's competition here
DTXMF vs IMPZY Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, IMPZY has a market cap of 199.9M. Regarding current trading prices, DTXMF is priced at $0.10, while IMPZY trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas IMPZY's P/E ratio is -1.60. In terms of profitability, DTXMF's ROE is -0.41%, compared to IMPZY's ROE of -2.86%. Regarding short-term risk, DTXMF is more volatile compared to IMPZY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check IMPZY's competition here
DTXMF vs PXMBF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, PXMBF has a market cap of 187.5M. Regarding current trading prices, DTXMF is priced at $0.10, while PXMBF trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas PXMBF's P/E ratio is 29.17. In terms of profitability, DTXMF's ROE is -0.41%, compared to PXMBF's ROE of +0.12%. Regarding short-term risk, DTXMF is more volatile compared to PXMBF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check PXMBF's competition here
DTXMF vs AVHHL Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, AVHHL has a market cap of 167.7M. Regarding current trading prices, DTXMF is priced at $0.10, while AVHHL trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas AVHHL's P/E ratio is -3.07. In terms of profitability, DTXMF's ROE is -0.41%, compared to AVHHL's ROE of -3.38%. Regarding short-term risk, DTXMF is more volatile compared to AVHHL. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check AVHHL's competition here
DTXMF vs CYBQF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CYBQF has a market cap of 160.1M. Regarding current trading prices, DTXMF is priced at $0.10, while CYBQF trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CYBQF's P/E ratio is -60.00. In terms of profitability, DTXMF's ROE is -0.41%, compared to CYBQF's ROE of -0.01%. Regarding short-term risk, DTXMF is more volatile compared to CYBQF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CYBQF's competition here
DTXMF vs EKDHF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, EKDHF has a market cap of 157.2M. Regarding current trading prices, DTXMF is priced at $0.10, while EKDHF trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas EKDHF's P/E ratio is 17.50. In terms of profitability, DTXMF's ROE is -0.41%, compared to EKDHF's ROE of +0.09%. Regarding short-term risk, DTXMF is more volatile compared to EKDHF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check EKDHF's competition here
DTXMF vs DMTRF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, DMTRF has a market cap of 154.9M. Regarding current trading prices, DTXMF is priced at $0.10, while DMTRF trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas DMTRF's P/E ratio is -9.86. In terms of profitability, DTXMF's ROE is -0.41%, compared to DMTRF's ROE of -0.24%. Regarding short-term risk, DTXMF is more volatile compared to DMTRF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check DMTRF's competition here
DTXMF vs AMEUF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, AMEUF has a market cap of 120.5M. Regarding current trading prices, DTXMF is priced at $0.10, while AMEUF trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas AMEUF's P/E ratio is -1.75. In terms of profitability, DTXMF's ROE is -0.41%, compared to AMEUF's ROE of -5.13%. Regarding short-term risk, DTXMF is more volatile compared to AMEUF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check AMEUF's competition here
DTXMF vs SNZZF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, SNZZF has a market cap of 114.8M. Regarding current trading prices, DTXMF is priced at $0.10, while SNZZF trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas SNZZF's P/E ratio is -7.30. In terms of profitability, DTXMF's ROE is -0.41%, compared to SNZZF's ROE of -0.40%. Regarding short-term risk, DTXMF is more volatile compared to SNZZF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check SNZZF's competition here
DTXMF vs VMTHF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, VMTHF has a market cap of 110M. Regarding current trading prices, DTXMF is priced at $0.10, while VMTHF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas VMTHF's P/E ratio is -1.09. In terms of profitability, DTXMF's ROE is -0.41%, compared to VMTHF's ROE of -0.23%. Regarding short-term risk, DTXMF is more volatile compared to VMTHF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check VMTHF's competition here
DTXMF vs JMDMF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, JMDMF has a market cap of 104.4M. Regarding current trading prices, DTXMF is priced at $0.10, while JMDMF trades at $3.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas JMDMF's P/E ratio is -27.83. In terms of profitability, DTXMF's ROE is -0.41%, compared to JMDMF's ROE of N/A. Regarding short-term risk, DTXMF is more volatile compared to JMDMF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check JMDMF's competition here
DTXMF vs IPDQF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, IPDQF has a market cap of 104.2M. Regarding current trading prices, DTXMF is priced at $0.10, while IPDQF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas IPDQF's P/E ratio is -5.14. In terms of profitability, DTXMF's ROE is -0.41%, compared to IPDQF's ROE of -0.43%. Regarding short-term risk, DTXMF is more volatile compared to IPDQF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check IPDQF's competition here
DTXMF vs RSHUF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, RSHUF has a market cap of 91.5M. Regarding current trading prices, DTXMF is priced at $0.10, while RSHUF trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas RSHUF's P/E ratio is -5.81. In terms of profitability, DTXMF's ROE is -0.41%, compared to RSHUF's ROE of -2.32%. Regarding short-term risk, DTXMF is more volatile compared to RSHUF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check RSHUF's competition here
DTXMF vs SOMNF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, SOMNF has a market cap of 90.8M. Regarding current trading prices, DTXMF is priced at $0.10, while SOMNF trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas SOMNF's P/E ratio is -14.00. In terms of profitability, DTXMF's ROE is -0.41%, compared to SOMNF's ROE of -0.38%. Regarding short-term risk, DTXMF is more volatile compared to SOMNF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check SOMNF's competition here
DTXMF vs CKMTF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CKMTF has a market cap of 85.2M. Regarding current trading prices, DTXMF is priced at $0.10, while CKMTF trades at $12.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CKMTF's P/E ratio is -3.32. In terms of profitability, DTXMF's ROE is -0.41%, compared to CKMTF's ROE of +2.58%. Regarding short-term risk, DTXMF is more volatile compared to CKMTF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CKMTF's competition here
DTXMF vs FDMDF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, FDMDF has a market cap of 75.7M. Regarding current trading prices, DTXMF is priced at $0.10, while FDMDF trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas FDMDF's P/E ratio is -2.32. In terms of profitability, DTXMF's ROE is -0.41%, compared to FDMDF's ROE of -0.44%. Regarding short-term risk, DTXMF is more volatile compared to FDMDF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check FDMDF's competition here
DTXMF vs RDGL Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, RDGL has a market cap of 60.6M. Regarding current trading prices, DTXMF is priced at $0.10, while RDGL trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas RDGL's P/E ratio is -13.36. In terms of profitability, DTXMF's ROE is -0.41%, compared to RDGL's ROE of -1.57%. Regarding short-term risk, DTXMF is more volatile compared to RDGL. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check RDGL's competition here
DTXMF vs BLOZF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, BLOZF has a market cap of 50.8M. Regarding current trading prices, DTXMF is priced at $0.10, while BLOZF trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas BLOZF's P/E ratio is -22.06. In terms of profitability, DTXMF's ROE is -0.41%, compared to BLOZF's ROE of -0.89%. Regarding short-term risk, DTXMF is more volatile compared to BLOZF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check BLOZF's competition here
DTXMF vs BRNHF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, BRNHF has a market cap of 42.2M. Regarding current trading prices, DTXMF is priced at $0.10, while BRNHF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas BRNHF's P/E ratio is -1.33. In terms of profitability, DTXMF's ROE is -0.41%, compared to BRNHF's ROE of -0.09%. Regarding short-term risk, DTXMF is more volatile compared to BRNHF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check BRNHF's competition here
DTXMF vs NVYTF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, NVYTF has a market cap of 38.9M. Regarding current trading prices, DTXMF is priced at $0.10, while NVYTF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas NVYTF's P/E ratio is -0.74. In terms of profitability, DTXMF's ROE is -0.41%, compared to NVYTF's ROE of +0.00%. Regarding short-term risk, DTXMF is more volatile compared to NVYTF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check NVYTF's competition here
DTXMF vs TLTFF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, TLTFF has a market cap of 38.4M. Regarding current trading prices, DTXMF is priced at $0.10, while TLTFF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas TLTFF's P/E ratio is -15.30. In terms of profitability, DTXMF's ROE is -0.41%, compared to TLTFF's ROE of -2.57%. Regarding short-term risk, DTXMF is more volatile compared to TLTFF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check TLTFF's competition here
DTXMF vs ELXMF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, ELXMF has a market cap of 28.4M. Regarding current trading prices, DTXMF is priced at $0.10, while ELXMF trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas ELXMF's P/E ratio is -2.00. In terms of profitability, DTXMF's ROE is -0.41%, compared to ELXMF's ROE of -0.46%. Regarding short-term risk, DTXMF is more volatile compared to ELXMF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check ELXMF's competition here
DTXMF vs MKEAF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, MKEAF has a market cap of 25.9M. Regarding current trading prices, DTXMF is priced at $0.10, while MKEAF trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas MKEAF's P/E ratio is -4.11. In terms of profitability, DTXMF's ROE is -0.41%, compared to MKEAF's ROE of +0.50%. Regarding short-term risk, DTXMF is more volatile compared to MKEAF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check MKEAF's competition here
DTXMF vs EMITF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, EMITF has a market cap of 24.6M. Regarding current trading prices, DTXMF is priced at $0.10, while EMITF trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas EMITF's P/E ratio is -12.33. In terms of profitability, DTXMF's ROE is -0.41%, compared to EMITF's ROE of +0.05%. Regarding short-term risk, DTXMF is more volatile compared to EMITF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check EMITF's competition here
DTXMF vs KBBTF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, KBBTF has a market cap of 24.1M. Regarding current trading prices, DTXMF is priced at $0.10, while KBBTF trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas KBBTF's P/E ratio is -2.30. In terms of profitability, DTXMF's ROE is -0.41%, compared to KBBTF's ROE of N/A. Regarding short-term risk, DTXMF is more volatile compared to KBBTF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check KBBTF's competition here
DTXMF vs POSC Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, POSC has a market cap of 23.1M. Regarding current trading prices, DTXMF is priced at $0.10, while POSC trades at $1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas POSC's P/E ratio is 0.40. In terms of profitability, DTXMF's ROE is -0.41%, compared to POSC's ROE of +9.25%. Regarding short-term risk, DTXMF is more volatile compared to POSC. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check POSC's competition here
DTXMF vs GTHP Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, GTHP has a market cap of 19.7M. Regarding current trading prices, DTXMF is priced at $0.10, while GTHP trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas GTHP's P/E ratio is -5.00. In terms of profitability, DTXMF's ROE is -0.41%, compared to GTHP's ROE of +0.78%. Regarding short-term risk, DTXMF is more volatile compared to GTHP. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check GTHP's competition here
DTXMF vs ASAPF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, ASAPF has a market cap of 19.5M. Regarding current trading prices, DTXMF is priced at $0.10, while ASAPF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas ASAPF's P/E ratio is -25.00. In terms of profitability, DTXMF's ROE is -0.41%, compared to ASAPF's ROE of -0.23%. Regarding short-term risk, DTXMF is more volatile compared to ASAPF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check ASAPF's competition here
DTXMF vs MDXHF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, MDXHF has a market cap of 18.8M. Regarding current trading prices, DTXMF is priced at $0.10, while MDXHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas MDXHF's P/E ratio is -0.08. In terms of profitability, DTXMF's ROE is -0.41%, compared to MDXHF's ROE of +0.49%. Regarding short-term risk, DTXMF is more volatile compared to MDXHF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check MDXHF's competition here
DTXMF vs PYNKF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, PYNKF has a market cap of 18.1M. Regarding current trading prices, DTXMF is priced at $0.10, while PYNKF trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas PYNKF's P/E ratio is -0.87. In terms of profitability, DTXMF's ROE is -0.41%, compared to PYNKF's ROE of -1.58%. Regarding short-term risk, DTXMF is more volatile compared to PYNKF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check PYNKF's competition here
DTXMF vs DIZTF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, DIZTF has a market cap of 18M. Regarding current trading prices, DTXMF is priced at $0.10, while DIZTF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas DIZTF's P/E ratio is -11.16. In terms of profitability, DTXMF's ROE is -0.41%, compared to DIZTF's ROE of -2.22%. Regarding short-term risk, DTXMF is more volatile compared to DIZTF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check DIZTF's competition here
DTXMF vs VPTDF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, VPTDF has a market cap of 17.8M. Regarding current trading prices, DTXMF is priced at $0.10, while VPTDF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas VPTDF's P/E ratio is -5.34. In terms of profitability, DTXMF's ROE is -0.41%, compared to VPTDF's ROE of +1.70%. Regarding short-term risk, DTXMF is more volatile compared to VPTDF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check VPTDF's competition here
DTXMF vs TMDIF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, TMDIF has a market cap of 13.9M. Regarding current trading prices, DTXMF is priced at $0.10, while TMDIF trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas TMDIF's P/E ratio is -0.65. In terms of profitability, DTXMF's ROE is -0.41%, compared to TMDIF's ROE of -1.38%. Regarding short-term risk, DTXMF is more volatile compared to TMDIF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check TMDIF's competition here
DTXMF vs PLLWF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, PLLWF has a market cap of 13.3M. Regarding current trading prices, DTXMF is priced at $0.10, while PLLWF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas PLLWF's P/E ratio is -1.10. In terms of profitability, DTXMF's ROE is -0.41%, compared to PLLWF's ROE of -0.61%. Regarding short-term risk, DTXMF is more volatile compared to PLLWF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check PLLWF's competition here
DTXMF vs IMEXF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, IMEXF has a market cap of 11.9M. Regarding current trading prices, DTXMF is priced at $0.10, while IMEXF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas IMEXF's P/E ratio is N/A. In terms of profitability, DTXMF's ROE is -0.41%, compared to IMEXF's ROE of +0.20%. Regarding short-term risk, DTXMF is more volatile compared to IMEXF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check IMEXF's competition here
DTXMF vs ATBPF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, ATBPF has a market cap of 11.4M. Regarding current trading prices, DTXMF is priced at $0.10, while ATBPF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas ATBPF's P/E ratio is -0.86. In terms of profitability, DTXMF's ROE is -0.41%, compared to ATBPF's ROE of -0.40%. Regarding short-term risk, DTXMF is more volatile compared to ATBPF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check ATBPF's competition here
DTXMF vs LXXGF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, LXXGF has a market cap of 11.3M. Regarding current trading prices, DTXMF is priced at $0.10, while LXXGF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas LXXGF's P/E ratio is -0.85. In terms of profitability, DTXMF's ROE is -0.41%, compared to LXXGF's ROE of -1.23%. Regarding short-term risk, DTXMF is more volatile compared to LXXGF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check LXXGF's competition here
DTXMF vs RMSL Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, RMSL has a market cap of 10.4M. Regarding current trading prices, DTXMF is priced at $0.10, while RMSL trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas RMSL's P/E ratio is 0.68. In terms of profitability, DTXMF's ROE is -0.41%, compared to RMSL's ROE of -2.03%. Regarding short-term risk, DTXMF is more volatile compared to RMSL. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check RMSL's competition here
DTXMF vs NGMDF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, NGMDF has a market cap of 8.5M. Regarding current trading prices, DTXMF is priced at $0.10, while NGMDF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas NGMDF's P/E ratio is -3.74. In terms of profitability, DTXMF's ROE is -0.41%, compared to NGMDF's ROE of +0.36%. Regarding short-term risk, DTXMF is more volatile compared to NGMDF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check NGMDF's competition here
DTXMF vs FZMD Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, FZMD has a market cap of 7.4M. Regarding current trading prices, DTXMF is priced at $0.10, while FZMD trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas FZMD's P/E ratio is 2.00. In terms of profitability, DTXMF's ROE is -0.41%, compared to FZMD's ROE of +0.13%. Regarding short-term risk, DTXMF is more volatile compared to FZMD. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check FZMD's competition here
DTXMF vs ALRTF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, ALRTF has a market cap of 6.4M. Regarding current trading prices, DTXMF is priced at $0.10, while ALRTF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas ALRTF's P/E ratio is -0.33. In terms of profitability, DTXMF's ROE is -0.41%, compared to ALRTF's ROE of +0.52%. Regarding short-term risk, DTXMF is more volatile compared to ALRTF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check ALRTF's competition here
DTXMF vs QLIS Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, QLIS has a market cap of 5.5M. Regarding current trading prices, DTXMF is priced at $0.10, while QLIS trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas QLIS's P/E ratio is 2.22. In terms of profitability, DTXMF's ROE is -0.41%, compared to QLIS's ROE of -1.41%. Regarding short-term risk, DTXMF is more volatile compared to QLIS. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check QLIS's competition here
DTXMF vs RHNMF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, RHNMF has a market cap of 5.4M. Regarding current trading prices, DTXMF is priced at $0.10, while RHNMF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas RHNMF's P/E ratio is -0.95. In terms of profitability, DTXMF's ROE is -0.41%, compared to RHNMF's ROE of +15.91%. Regarding short-term risk, DTXMF is more volatile compared to RHNMF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check RHNMF's competition here
DTXMF vs VYCO Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, VYCO has a market cap of 4.3M. Regarding current trading prices, DTXMF is priced at $0.10, while VYCO trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas VYCO's P/E ratio is -13.00. In terms of profitability, DTXMF's ROE is -0.41%, compared to VYCO's ROE of +0.03%. Regarding short-term risk, DTXMF is more volatile compared to VYCO. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check VYCO's competition here
DTXMF vs NUMD Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, NUMD has a market cap of 4.2M. Regarding current trading prices, DTXMF is priced at $0.10, while NUMD trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas NUMD's P/E ratio is 5.00. In terms of profitability, DTXMF's ROE is -0.41%, compared to NUMD's ROE of +0.35%. Regarding short-term risk, DTXMF is more volatile compared to NUMD. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check NUMD's competition here
DTXMF vs LBLTF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, LBLTF has a market cap of 4.1M. Regarding current trading prices, DTXMF is priced at $0.10, while LBLTF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas LBLTF's P/E ratio is -0.01. In terms of profitability, DTXMF's ROE is -0.41%, compared to LBLTF's ROE of +0.00%. Regarding short-term risk, DTXMF is more volatile compared to LBLTF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check LBLTF's competition here
DTXMF vs ADMT Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, ADMT has a market cap of 4M. Regarding current trading prices, DTXMF is priced at $0.10, while ADMT trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas ADMT's P/E ratio is -5.87. In terms of profitability, DTXMF's ROE is -0.41%, compared to ADMT's ROE of -0.63%. Regarding short-term risk, DTXMF is more volatile compared to ADMT. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check ADMT's competition here
DTXMF vs BIEL Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, BIEL has a market cap of 3.6M. Regarding current trading prices, DTXMF is priced at $0.10, while BIEL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas BIEL's P/E ratio is N/A. In terms of profitability, DTXMF's ROE is -0.41%, compared to BIEL's ROE of +0.04%. Regarding short-term risk, DTXMF is more volatile compared to BIEL. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check BIEL's competition here
DTXMF vs VANIW Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, VANIW has a market cap of 3.4M. Regarding current trading prices, DTXMF is priced at $0.10, while VANIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas VANIW's P/E ratio is N/A. In terms of profitability, DTXMF's ROE is -0.41%, compared to VANIW's ROE of -1.33%. Regarding short-term risk, DTXMF is more volatile compared to VANIW. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check VANIW's competition here
DTXMF vs PMEDF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, PMEDF has a market cap of 3.3M. Regarding current trading prices, DTXMF is priced at $0.10, while PMEDF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas PMEDF's P/E ratio is -1.69. In terms of profitability, DTXMF's ROE is -0.41%, compared to PMEDF's ROE of +1.68%. Regarding short-term risk, DTXMF is more volatile compared to PMEDF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check PMEDF's competition here
DTXMF vs TBRIF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, TBRIF has a market cap of 3.2M. Regarding current trading prices, DTXMF is priced at $0.10, while TBRIF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas TBRIF's P/E ratio is -0.84. In terms of profitability, DTXMF's ROE is -0.41%, compared to TBRIF's ROE of -2.28%. Regarding short-term risk, DTXMF is more volatile compared to TBRIF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check TBRIF's competition here
DTXMF vs ESMC Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, ESMC has a market cap of 3M. Regarding current trading prices, DTXMF is priced at $0.10, while ESMC trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas ESMC's P/E ratio is 8.00. In terms of profitability, DTXMF's ROE is -0.41%, compared to ESMC's ROE of +0.00%. Regarding short-term risk, DTXMF is more volatile compared to ESMC. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check ESMC's competition here
DTXMF vs ODYY Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, ODYY has a market cap of 2.3M. Regarding current trading prices, DTXMF is priced at $0.10, while ODYY trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas ODYY's P/E ratio is -0.16. In terms of profitability, DTXMF's ROE is -0.41%, compared to ODYY's ROE of +2.30%. Regarding short-term risk, DTXMF is more volatile compared to ODYY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check ODYY's competition here
DTXMF vs USAQ Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, USAQ has a market cap of 2.3M. Regarding current trading prices, DTXMF is priced at $0.10, while USAQ trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas USAQ's P/E ratio is -5.00. In terms of profitability, DTXMF's ROE is -0.41%, compared to USAQ's ROE of +0.67%. Regarding short-term risk, DTXMF is more volatile compared to USAQ. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check USAQ's competition here
DTXMF vs CRRVF Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CRRVF has a market cap of 1.5M. Regarding current trading prices, DTXMF is priced at $0.10, while CRRVF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CRRVF's P/E ratio is N/A. In terms of profitability, DTXMF's ROE is -0.41%, compared to CRRVF's ROE of +0.00%. Regarding short-term risk, DTXMF is more volatile compared to CRRVF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CRRVF's competition here
DTXMF vs LLBO Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, LLBO has a market cap of 1.3M. Regarding current trading prices, DTXMF is priced at $0.10, while LLBO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas LLBO's P/E ratio is N/A. In terms of profitability, DTXMF's ROE is -0.41%, compared to LLBO's ROE of +0.00%. Regarding short-term risk, DTXMF is more volatile compared to LLBO. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check LLBO's competition here
DTXMF vs CYDX Comparison July 2025
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CYDX has a market cap of 1.3M. Regarding current trading prices, DTXMF is priced at $0.10, while CYDX trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CYDX's P/E ratio is 0.33. In terms of profitability, DTXMF's ROE is -0.41%, compared to CYDX's ROE of +0.17%. Regarding short-term risk, DTXMF is more volatile compared to CYDX. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CYDX's competition here